Home › Companies › FBIO

Fortress Biotech

FBIO Rare disease Lead: Approved ★ Read the deep dive → 4 Biotech Distilled articles ↓

Dermatology Hematology Metabolic Cell Protein Small Molecule

Most recent annual filing: 2026-03-31

Pipeline (12 active programs)

Emrosi

minocycline hydrochloride extended-release capsules · Minocycline Hydrochloride Modified Release Capsules · DFD-29

Rosacea Approved oral

UNLOXCYT

cosibelimab-ipdl

Protein Target: PD-L1

Undisclosed indication Approved Sun Pharma

ZYCUBO

copper histidinate injection · copper histidinate · CUTX-101

Menkes Disease Approved intravenous Sentynl Therapeutics

anselamimab

CAEL-101

Protein Target: light chain fibrils

AL Amyloidosis

dotinurad

Small Molecule Target: URAT1

Gout

triplex

Protein Target: cytomegalovirus

Undisclosed indication

MB-109

Cell Target: IL13Rα2

Undisclosed indication

AJ201

Small Molecule Target: Nrf1, Nrf2, androgen receptor

Undisclosed indication

BAER-101

Small Molecule Target: GABAA α2/3

Undisclosed indication

clenbuterol

ATX-04

Small Molecule Target: β2-adrenergic receptor

Pompe Disease Preclinical Duke University

Amzeeq

Undisclosed indication Approved

Zilxi

Undisclosed indication Approved

Biotech Distilled coverage (4)

2026-05-15 UPDATE: Fortress Biotech (FBIO) - The Parent Balance Sheet Finally Prints 🔒 Paid
2026-05-14 UPDATE: Fortress Biotech (FBIO) - Journey Hits Positive EBITDA, Emrosi Triples YoY 🔒 Paid
2026-04-27 UPDATE: Fortress Biotech (FBIO) - The PRV Cash Lands, The Covenants Vanish, The Stock Bleeds Anyway 🔒 Paid
2026-02-24 Fortress Biotech (FBIO): Scientific Deep Dive for Lead and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.